

sTable 1. Adverse Events Following BCMA/GPRC5D CAR T-Cell Therapy.

	Any, No.(%)	1-2, No.(%)	3-4, No.(%)
Leukopenia	9 (100)	0	9 (100)
Neutropenia	9 (100)	0	9 (100)
Lymphopenia	7 (77.8)	2 (22.2)	5 (55.6)
Anaemia	9 (100)	1 (11.1)	8 (88.9)
Thrombocytopenia	8 (88.9)	1 (11.1)	7 (77.8)
Gastrointestinal disorders	4 (44.5)	3 (33.3)	1 (11.1)
Nausea	4 (44.5)	3 (33.3)	1 (11.1)
Constipation	0	0	0
Diarrhea	0	0	0
Abdominal distension	1 (11.1)	1 (11.1)	0
Hypophosphatemia	0	0	0
Hypokalaemia	8 (88.9)	8 (88.9)	0
Hypocalcaemia	8 (88.9)	8 (88.9)	0
Elevated aspartate aminotransferase	5 (55.6)	5 (55.6)	0
Elevated alanine aminotransferase	1 (11.1)	1 (11.1)	0
Decreased fibrinogen	3 (33.3)	3 (33.3)	0
APTT extension	2 (22.2)	2 (22.2)	0
Palm and sole peeling	0	0	0
Nail changes	0	0	0
Headache	2 (22.2)	2 (22.2)	0
ICANS	1 (11.1)	1 (11.1)	0
CRS	6 (66.7)	5 (55.6)	1 (11.1)
Dysgeusia	0	0	0
Cerebellar toxicity	0	0	0
Non-ICANS neurotoxicity	0	0	0